Daniele, Stefano G.
Kim, Sa Rang
Grada, Ayman
Moore, Angela Y.
Suozzi, Kathleen C.
Bunick, Christopher G. http://orcid.org/0000-0002-4011-8308
Funding for this research was provided by:
Foundation for the National Institutes of Health (T32GM136651)
Article History
Accepted: 27 November 2022
First Online: 20 December 2022
Declarations
:
: No sources of funding were received for the preparation of this article.
: SGD, SRK, AG, and KCS have no disclosures; AYM has received funds, honoraria, or research grants as an advisory board member (A), consultant (C), clinical study investigator (I), and/or speaker (SP) for Almirall, Biofronterra, and Galderma; CGB has served as an (I) for Almirall; a (C) for AbbVie, Almirall, Arcutis, EpiHealth, LEO Pharma, Sanofi-Regeneron, and UCB; and a (SP) for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. These engagements did not influence the writing of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: SGD, SRK, AG, AYM, KCS, and CGB researched and/or provided data for the article. SGD and SRK wrote the first draft of the article. All authors contributed substantially to discussion of the content and reviewed and/or edited the manuscript before submission.